Cardiology Medical News about beta-blocker therapy;distinct myocardial effects;heart failure;normal and reduced left ventricular ejection fraction

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death

3. The Job Market for 2008-2009: Compensation

4. Renal Artery Stenosis

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction
European Heart Journal, 06/05/09

Hamdani N et al. – Myocardial effects unique to either heart failure (HF) with normal left ventricular ejection fraction (LVEF) (HFNEF) or HF with reduced LVEF (HFREF) may contribute to the dissimilar outcome of beta-blocker therapy in both HF phenotypes.

Methods

Study of whether beta-blockers have distinct myocardial effects in HFNEF and HFREF, myocardial structure, cardiomyocyte function, and myocardial protein composition in HFNEF and HFREF pts with/without beta-blockers free of coronary artery disease
Pt classification: 16 beta-HFNEF, 16 beta+HFNEF, 17 beta-HFREF, 22 beta+HFREF
LV endomyocardial biopsies for collagen volume fraction (CVF) and cardiomyocyte diameter (MyD) by histomorphometry, phosphorylation of myofilamentary proteins by ProQ-Diamond phosphostained 1D-gels, and expression of beta-adrenergic signalling and calcium handling proteins by western immunoblotting
Cardiomyocytes isolated from biopsies to measure active force (Factive), resting force (Fpassive), and calcium sensitivity (pCa50)

Results

Myocardial effects of beta-blocker therapy either shared by HFNEF and HFREF, unique to HFNEF or unique to HFREF
Shared: higher Factive, higher pCa50, lower phosphorylation of troponin I and myosin-binding protein C, and lower beta-2 adrenergic receptor expression
Unique to HFNEF: higher Fpassive, lower CVF, lower MyD, and lower expression of stimulatory G protein
Unique to HFREF: lower expression of inhibitory G protein

<< Previous
New antithrombotic agents: Are they needed and what can they...

Next >>
High high-density lipoprotein-cholesterol reduces risk and extent...

Is Pretreatment with Beta-Blockers Beneficial in Patients with Acute Coronary Syndrome
Cardiology, 11/13/09 Relevance Score: 65%%

Use of Combination Therapy with a beta-Blocker and Milrinone in Patients with Advanced Heart Failure
Annals of Pharmacotherapy, 10/13/09 Relevance Score: 65%%

Management of hypertension in the elderly patient
Clinical Interventions in Aging, 10/01/09 Relevance Score: 65%%

Respiratory Effects of beta-blocker Therapy in Heart Failure
Cardiovascular Drugs and Therapy, 10/06/09 Relevance Score: 64%%

Pharmacodynamic Interactions with Exercise and Beta-Blocker Medications
American Journal of Lifestyle Medicine, 11/16/09 Relevance Score: 63%%